Genetically engineered virus kills liver cancer

Via avordvet

 

 Genetically engineered virus kills liver cancer in Cancer A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.

Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose. "For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients," study co-author David Kirn told AFP. 

The four-week trial with the vaccine Pexa-Vec or JX-594, reported in the journal Nature Medicine, may hold promise for the treatment of advanced solid tumours. "Despite advances in cancer treatment over the past 30 years with chemotherapy and biologics, the majority of solid tumours remain incurable once they are metastatic (have spread to other organs)," the authors wrote. 

There was a need for the development of "more potent active immunotherapies", they noted. Pexa-Vec "is designed to multiply in and subsequently destroy cancer cells, while at the same time making the patients' own immune defence system attack cancer cells also," said Kirn from California-based biotherapy company Jennerex.

                                                          More @ Medical Press

Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose. "For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients," study co-author David Kirn told AFP. The four-week trial with the vaccine Pexa-Vec or JX-594, reported in the journal Nature Medicine, may hold promise for the treatment of advanced solid tumours. "Despite advances in cancer treatment over the past 30 years with chemotherapy and biologics, the majority of solid tumours remain incurable once they are metastatic (have spread to other organs)," the authors wrote. There was a need for the development of "more potent active immunotherapies", they noted.

Read more at: http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html#jCp

Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose. "For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients," study co-author David Kirn told AFP. The four-week trial with the vaccine Pexa-Vec or JX-594, reported in the journal Nature Medicine, may hold promise for the treatment of advanced solid tumours. "Despite advances in cancer treatment over the past 30 years with chemotherapy and biologics, the majority of solid tumours remain incurable once they are metastatic (have spread to other organs)," the authors wrote. There was a need for the development of "more potent active immunotherapies", they noted.

Read more at: http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html#jCp

Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose. "For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients," study co-author David Kirn told AFP. The four-week trial with the vaccine Pexa-Vec or JX-594, reported in the journal Nature Medicine, may hold promise for the treatment of advanced solid tumours. "Despite advances in cancer treatment over the past 30 years with chemotherapy and biologics, the majority of solid tumours remain incurable once they are metastatic (have spread to other organs)," the authors wrote. There was a need for the development of "more potent active immunotherapies", they noted.

Read more at: http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html#jCp

A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.

Read more at: http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html#jCp

A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.

Read more at: http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html#jCp

A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.

Read more at: http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html#jCp